Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, Doornfontein, 2028, Johannesburg, South Africa.
Bioprospecting laboratory, Department of Botany, Bharathiar University, Coimbatore, Tamil Nadu, 641046, India.
Biomed Pharmacother. 2017 Nov;95:167-174. doi: 10.1016/j.biopha.2017.08.061. Epub 2017 Sep 12.
Plants are considered as one of the best sources of diabetic therapy. Being a reliable and sustainable medicinal hub, this study directs the use of Syzygium mundagam in exploring the antidiabetic property. Streptozotocin-Nicotinamide (STZ-NA) induced diabetic rats were treated with Syzygium mundagam bark methanol extract (SMBM). Based on acute toxicity study, the doses of the extract were fixed as 100 and 200mg/kg. Glibenclamide was used as reference drug. The blood glucose level and body weight of the rats were monitored for 28days. After the treatment, rats were sacrificed and the blood biochemical, serum and histopathological parameters were analysed. The in vivo antioxidant levels in liver and kidney were also estimated. SMBM extract (200mg/kg) could significantly reduce the blood glucose level from 580.60mg/dL to 237.60mg/dL on day 28. An accelerated reduction in body weight was observed in diabetic control rats and inhibited by the extract during the study. The haematological parameters were normal compared to normal rats. The values of serum parameters like triglycerides, high-density lipoprotein (HDL), cholesterol and very low-density lipoprotein (VLDL) were close to the values of normal rats. After the treatment, Superoxide dismutase (SOD), Glutathione (GSH) and Glutathione reductase (GR) levels in liver and kidney were found accountable for their antioxidant properties during diabetic condition. The degree of protection set by SMBM extract was clear enough in the histopathology of liver, kidney and pancreas. The phenolic compounds studied in SMBM can be related to these activities. This study proves the ability of Syzygium mundagam to combat the diabetic condition and provides an insight on hidden properties of plants which can be utilized as novel drugs for existing disease complications.
植物被认为是糖尿病治疗的最佳来源之一。作为一个可靠和可持续的药用中心，本研究指导使用 Syzygium mundagam 来探索其抗糖尿病特性。链脲佐菌素-烟酰胺（STZ-NA）诱导的糖尿病大鼠用 Syzygium mundagam 树皮甲醇提取物（SMBM）治疗。基于急性毒性研究，确定提取物的剂量为 100 和 200mg/kg。格列本脲用作参考药物。监测大鼠的血糖水平和体重 28 天。治疗后，处死大鼠，分析血液生化、血清和组织病理学参数。还估计了肝和肾中的体内抗氧化水平。SMBM 提取物（200mg/kg）可使血糖水平从第 28 天的 580.60mg/dL 显著降低至 237.60mg/dL。糖尿病对照组大鼠体重迅速下降，提取物在研究期间抑制了体重下降。与正常大鼠相比，血液参数正常。血清参数如甘油三酯、高密度脂蛋白（HDL）、胆固醇和极低密度脂蛋白（VLDL）的值接近正常大鼠的值。治疗后，肝和肾中的超氧化物歧化酶（SOD）、谷胱甘肽（GSH）和谷胱甘肽还原酶（GR）水平可归因于其在糖尿病状态下的抗氧化特性。SMBM 提取物在肝、肾和胰腺的组织病理学中提供的保护程度足以说明问题。在 SMBM 中研究的酚类化合物可能与这些活性有关。本研究证明了 Syzygium mundagam 对抗糖尿病的能力，并提供了对植物隐藏特性的深入了解，这些特性可用于治疗现有疾病并发症的新型药物。
